IMMIX BIOPHARMA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.095 USD | -3.46% |
|
-0.94% | -69.51% |
| Apr. 29 | Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment | MT |
| Apr. 18 | Immix Biopharma on Track to Dose First Patients with AL Amyloidosis Therapy by Mid-Year | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 47.02 | 31.89 | 137.5 | 57.3 | - | - |
| Enterprise Value (EV) 1 | 47.02 | 18.46 | 120 | 45.31 | 71.9 | 57.3 |
| P/E ratio | -0.54 x | -3.88 x | -7.78 x | -2.33 x | -2.3 x | -5.86 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | 4.72 x |
| EV / Revenue | - | - | - | - | - | 4.72 x |
| EV / EBITDA | - | -2.25 x | -7.44 x | -2.06 x | -2.75 x | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 13,209 | 13,927 | 19,867 | 26,404 | - | - |
| Reference price 2 | 3.560 | 2.290 | 6.920 | 2.170 | 2.170 | 2.170 |
| Announcement Date | 3/28/22 | 3/27/23 | 3/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 12.14 |
| EBITDA 1 | - | -8.217 | -16.14 | -21.96 | -26.16 | - |
| EBIT 1 | - | -8.219 | -16.14 | -21.96 | -23.43 | -10.1 |
| Operating Margin | - | - | - | - | - | -83.2% |
| Earnings before Tax (EBT) 1 | - | -8.219 | -15.57 | -21.44 | -23.62 | -10.1 |
| Net income 1 | -24.38 | -8.23 | -15.43 | -21.47 | -23.65 | -10.1 |
| Net margin | - | - | - | - | - | -83.2% |
| EPS 2 | -6.640 | -0.5900 | -0.8900 | -0.9300 | -0.9450 | -0.3700 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/28/22 | 3/27/23 | 3/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -3.795 | -2.521 | -3.721 | -4.524 | -5.376 | -4.679 | -4.77 | -4.863 | -4.959 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -3.795 | -2.493 | -3.592 | -4.337 | -5.147 | -4.679 | -4.77 | -4.863 | -4.959 |
| Net income 1 | -1.535 | -3.8 | -2.48 | -3.576 | -4.281 | -5.09 | -4.685 | -4.776 | -4.87 | -4.965 |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.1100 | -0.2700 | -0.1800 | -0.2400 | -0.2300 | -0.2400 | -0.2300 | -0.2200 | -0.2200 | -0.2200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/22 | 3/27/23 | 5/12/23 | 8/11/23 | 11/13/23 | 3/29/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 14.6 | - |
| Net Cash position 1 | - | 13.4 | 17.5 | 12 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.5582 x | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | - | 0.05 | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 3/28/22 | 3/27/23 | 3/29/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.17
USD
Average target price
14
USD
Spread / Average Target
+545.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -69.51% | 57.28M | |
| -4.24% | 86.85B | |
| +2.76% | 40.16B | |
| -16.59% | 31.28B | |
| +57.86% | 25.27B | |
| -14.76% | 15.33B | |
| -9.12% | 11.96B | |
| -42.56% | 11.61B | |
| +6.89% | 8.83B | |
| -10.53% | 7.94B |
- Stock Market
- Equities
- IMMX Stock
- Financials Immix Biopharma, Inc.
